此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

在肯尼亚,辅助5-氟尿嘧啶联合热消融改善HIV女性患者HPV治疗结果 (ASCEND)

2026年11月16日 更新者:UNC Lineberger Comprehensive Cancer Center

辅助性5-氟尿嘧啶联合热消融治疗改善肯尼亚HIV感染女性HPV治疗结局

This randomized, placebo-controlled trial will evaluate self-administered 5-fluorouracil (5FU) to improve human papillomavirus (HPV) clearance after thermal ablation (TA) in Women With Human Immunodeficiency Virus (HIV) (WWH) in Kenya. The trial will also assess the safety, adherence, and acceptability of 5FU. Starting four weeks after TA, participants will self-administer 5FU cream or matched placebo intravaginally once every other week for 12 applications, with clinic visits at weeks 2, 8, 16, 24, and 48 for evaluation. All participants will be followed up to 48 weeks.

It is hypothesized that, compared to placebo, 5FU will increase HPV clearance at 24 weeks and that the proposed dosing schedule will be safe, well-tolerated, and acceptable in this population. Together with data from other studies, this trial will provide evidence on the use of self-administered intravaginal 5FU to improve HPV treatment outcomes in WWH in low- and middle-income countries, where the burden of cervical cancer is highest.

研究概览

详细说明

WWH face up to six times higher risk of cervical cancer, a leading cause of death in this population. Cervical cancer is caused by persistent HPV infection, which can lead to cervical intraepithelial neoplasia grade 2/3 (CIN2/3), also called cervical precancer. If untreated, CIN2/3 can progress to cervical cancer. Thermal ablation (TA) is the most commonly used treatment for HPV/precancer in low- and middle-income countries, including Kenya. However, among WWH, TA has suboptimal efficacy, with only 44-66% clearing HPV or CIN2/3 at 6-12 months, compared to 83-95% in women without HIV. This highlights the need for adjuvant therapies to improve outcomes.

Studies in high-income countries suggest that off-label, self-administered intravaginal 5FU cream can improve HPV and CIN2/3 treatment outcomes in both HIV-negative and HIV-positive women. This trial will evaluate its potential as an adjuvant therapy following TA in WWH.

研究类型

介入性

注册 (估计的)

140

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

      • Kisumu、肯尼亚
        • Nyanza Reproductive Health Society
        • 首席研究员:
          • Chemtai Mungo, MD, MPH
        • 接触:
      • Kisumu、肯尼亚、614-40100
        • Maseno University
        • 接触:
        • 首席研究员:
          • Jackton Omoto, MBChB

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

25年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

女性

描述

Inclusion Criteria

  • Women aged 25 years or older
  • Known HIV-positive status
  • On antiretroviral therapy (ART) for at least 60 days prior to enrollment
  • Positive HPV screening test screening result
  • Able to provide informed consent in English, Swahili, or Dholuo
  • Agree to use dual contraception during dosing phase if of childbearing potential
  • Planning to remain in study locale for duration of study (48 weeks) Exclusion Criteria
  • Current pregnancy or breastfeeding
  • History of anogenital cancer (cervical, vulvar, or anal)
  • Current use of immunosuppressive medications
  • History of total hysterectomy
  • Known allergy to 5FU
  • Medical comorbidity that would interfere with study participation
  • Unwilling or unable to use contraception during study participation

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:双倍的

武器和干预

参与者组/臂
干预/治疗
实验性的:5% 5-fluorouracil

Participants will receive 12 doses of intravaginal 5FU cream.

Starting four weeks after thermal ablation, participants will self-administer 2 g of 5FU cream intravaginally once every two weeks for 12 doses.

安慰剂比较:Placebo cream

Participants will receive 12 doses of intravaginal placebo cream.

Starting four weeks after thermal ablation, participants will self-administer 2g of placebo cream intravaginally once every two weeks for 12 doses.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
High-risk human papillomavirus (hrHPV) Clearance among WWH randomized to adjuvant self-administered 5FU cream versus placebo cream following Thermal ablation (TA)
大体时间:Up to 24 weeks

Vaginal samples will be collected at baseline and approximately every four weeks. Clearance of hrHPV genotypes will be assessed using Polymerase Chain Reaction (PCR)-based human papillomavirus (HPV) Deoxyribonucleic Acid (DNA) testing on these follow-up samples.

Up to 24 weeks

次要结果测量

结果测量
措施说明
大体时间
Adverse Event per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0
大体时间:24 weeks

Type, frequency, severity and duration of adverse events (AEs) using NCI CTCAE v5.0 will be reported. The NCI Common Terminology Criteria for Adverse Events is a descriptive terminology which can be utilized for Adverse Event (AE) reporting. A grading (severity) scale is provided for each AE term. Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental Activities of Daily Living (ADL). Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL. Grade 4 Life-threatening consequences; urgent intervention indicated. Grade 5 Death related to AE.

24 weeks
Adverse Event per National Institute of Health (NIH) Division of Acquired Immunodeficiency Syndrome (AIDS) Adverse Event Grading Criteria (DAIDS)
大体时间:Up to 24 weeks

Type, frequency, severity and duration of adverse events (AEs) using per DAIDS standardized scales will be reported.

The DAIDS grading table provides an AE severity grading scale ranging from grades 1 to 5 with descriptions for each AE based on the following general guidelines: Grade 1 indicates a mild event, Grade 2 indicates a moderate event, Grade 3 indicates a severe event, Grade 4 indicates a potentially life-threatening event, Grade 5 indicates death.

Up to 24 weeks
Number of successful self-administration of the intravaginal cream by participants
大体时间:Up to 24 weeks

Number of confirmed successful self-administrations of intravaginal 5FU or placebo cream by participants.

Up to 24 weeks

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Chemtai Mungo, MD, MPH、UNC Lineberger Comprehensive Cancer Center

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年12月1日

初级完成 (估计的)

2027年9月1日

研究完成 (估计的)

2028年3月1日

研究注册日期

首次提交

2026年4月15日

首先提交符合 QC 标准的

2026年4月15日

首次发布 (实际的)

2026年4月22日

研究记录更新

最后更新发布 (实际的)

2026年11月17日

上次提交的符合 QC 标准的更新

2026年11月16日

最后验证

2026年11月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅